Ardelyx Stock News

This is what penny stocks need to succeed in 2022 The post What Do Penny Stocks Need to Succeed in 2022?  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Recent analyst upgrades suggest these stocks can triple your money or better.

Recent analyst upgrades suggest these stocks can triple your money or better.

Gainers PaxMedica, Inc. (NASDAQ: PXMD) gained 53.5% to $2.38 after the company announced an equity investment agreement for up to $20 million with Lincoln Park Capital. Satixfy Communications Ltd. (N

The FDA's CRDAC recommends granting marketing approval to Ardelyx's (ARDX) oral pill to control serum phosphorus in adult patients with chronic kidney disease on dialysis.

Piper Sandler raised its price target on Ardelyx Inc (NASDAQ: ARDX) to $8 from $3 and upgraded to Overweight from a Neutral rating. The upgrade follows a surprisingly positive advisory committee

Gainers Satixfy Communications Ltd. (NYSE: SATX) jumped 96.4% to settle at $51.70 on Thursday. Elevate Credit, Inc. (NYSE: ELVT) shares jumped 68.9% to close at $1.79 on Thursday after the company ag

U.S. stocks closed slightly lower on Thursday, with the S&P 500 dropping around 0.3%. Here is the list of some big stocks recording gains in the previous session. Satixfy Communications Ltd. (NYSE: S

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite dropping around 60 points on Thursday. The Dow traded down 0.18% to 33,491.86 while the NASDAQ fell 0.54% to 11,123.49. Th

Gainers Elevate Credit, Inc. (NYSE: ELVT) shares surged 71.2% to $1.8150 after the company agreed to be acquired by Park Cities Asset Management in an all-cash transaction at an implied value of $67

U.S. stocks traded lower midway through trading, with the S&P 500 dropping around 1% on Thursday. The Dow traded down 0.53% to 33,377.30 while the NASDAQ fell 0.85% to 11,088.75. The S&P 500 also fell

Upgrades Wolfe Research upgraded the previous rating for Matson Inc (NYSE:MATX) from Underperform to Peer Perform. In the third quarter, Matson showed an EPS of $6.89, compared to $6.53 from the year-

Ardelyx Inc saw its value soar today after the US Food and Drug Administration's (FDA) advisory panel recommended the approval of the group's drug for chronic kidney disease patients on dialysis, m

Gainers Ardelyx Inc (NASDAQ: ARDX) shares rose 81.2% to $2.21 in pre-market trading as the company said the FDA Advisory Committee voted 9-To-4 that the benefits of XPHOZAH outweigh its risks for the

U.S. stock futures traded lower this morning. Here are some big stocks recording gains in today’s pre-market trading session. Ardelyx Inc (NASDAQ: ARDX) shares jumped 81.2% to $2.21 in pre-market t